Related Experiment Videos
Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction
Insights
Epoprostenol (prostacyclin) infusion did not improve outcomes for acute myocardial infarction patients within 16 hours of symptom onset. This pilot study found no significant benefits in mortality or cardiac events, though it was well-tolerated.
Area of Science:
- Cardiology
- Pharmacology
- Critical Care Medicine
Background:
- Epoprostenol (prostacyclin) inhibits platelet aggregation and relaxes vascular smooth muscle.
- These properties suggest potential benefits for patients experiencing acute myocardial infarction (AMI).
Purpose of the Study:
- To evaluate the efficacy and safety of epoprostenol infusion in patients with acute myocardial infarction.
- To determine if early administration of epoprostenol impacts mortality, cardiac events, or cardiac function.
Main Methods:
- A randomized, double-blind, placebo-controlled study involving 45 AMI patients.
- Patients received a 72-hour infusion of epoprostenol or placebo within 16 hours of symptom onset.
- Outcomes including mortality, heart failure, shock, arrhythmias, and cardiac enzyme levels were monitored for 30 days.
Main Results:
- No significant differences were observed between the epoprostenol and placebo groups in mortality, congestive heart failure, cardiogenic shock, arrhythmias, recurrent chest pain, or reinfarction.
- Peak creatine kinase levels and time to peak levels did not differ significantly between groups.
- Facial flushing was the primary side effect noted in the epoprostenol group; the drug was generally well-tolerated.
Conclusions:
- Early epoprostenol infusion in acute myocardial infarction patients, within 16 hours of symptom onset, did not demonstrate significant clinical benefits at the doses used.
- The study suggests epoprostenol is well-tolerated in this patient population.
- Further research may be needed to explore different dosing strategies or patient subgroups.
Abstract:
Epoprostenol (prostacyclin) is a potent inhibitor of platelet aggregation and causes relaxation of vascular smooth muscle. These effects may be beneficial in patients with acute myocardial infarction. The effect of epoprostenol infusion in patients with acute myocardial infarction was evaluated in a randomised double blind study of 45 patients with evidence of myocardial infarction of less than 16 hours' duration. The patients were given a 72 hour infusion of epoprostenol (23) or placebo (22). The maximum dose was 5 ng/kg/min. The mean time to treatment was 8.3 hours (range 3.8-15.9 hours). The mean dose was 4.9 ng/kg/min. The patients were followed until day 30. No significant differences were found between the groups in mortality, development of congestive heart failure, cardiogenic shock, arrhythmias, recurrent chest pain, reinfarction, peak creatine kinase concentration, or the time taken to attain peak creatine kinase concentration. No significant difference in baseline ejection fraction was noted between groups, and no significant change in ejection fraction occurred within each group or between groups. The only significant side effect was the development of facial flushing in the epoprostenol group. In this pilot study epoprostenol was well tolerated by patients with acute myocardial infarction. No benefit from epoprostenol could be demonstrated at the dose range used when the drug was administered within 16 hours of the onset of symptoms.